All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The anti-IL-2 antibody JES-6 demonstrates attenuation of GvHD while preserving GvL

Jun 30, 2021

Graft-versus-host disease (GvHD) remains a significant challenge following allogeneic hematopoietic cell transplantation (HCT). Prophylaxis and treatment strategies for GvHD also need to preserve graft-versus-leukemia (GvL) activity.1 Multiple molecular targets have emerged for GvHD, including the interaction of programmed cell death-ligand 1 (PD-L1), expressed in GvHD target tissues, with programmed cell death protein 1 (PD-1), expressed on donor CD4+ and CD8+ T cells. PD-L1/PD1 interaction generates T-cell exhaustion, anergy, and apoptosis to reduce GvHD activity. Alongside this, blocking interleukin-2 (IL-2) signaling in donor T cells may augment the PD-L1/PD1 interaction to synergistically attenuate GvHD. GvL activity, conversely, requires the proliferation and preservation of donor CD8+ and CD4+ T memory progenitor (Tmp) cells and T effector (Teff) cells in lymphoid tissues.

Song et al. recently published their findings in Blood, investigating the use of an anti-IL-2 monoclonal antibody, JES-6, in a preclinical murine model of GvHD.1 JES-6 interferes with IL-2 and dimeric IL-2 receptor interaction, through beta and gamma subunits, but not alpha. It is of interest to investigate whether the interference of IL-2 interaction with IL-2Rβ and IL-2Rγ receptors, expressed on donor T cells, can attenuate GvHD while also preserving GvL activity in lymphoid tissues. The role of PD-L1 was also investigated to differentiate independent and synergic mechanisms of GvHD attenuation. We summarise key findings of this study below.1

Study design

The authors performed a series of experiments with a primary goal to test whether JES-6 treatment attenuates GvHD and preserves GvL activity. The following questions were investigated.

  1. Does JES-6 attenuate GvHD?
    • A murine model was used with BALB/c (H-2d) and C57BL/6 (H-2b) mice to create a histocompatibility mismatch. JES-6 treatment was compared with immunoglobulin G (IgG) and anti-IL-2-S4B6 controls, focusing on symptom reduction and tissue damage in GvHD target tissues.
  2. Does JES-6 preserve GvL?
    • Mice were inoculated with luciferase-transfected BCL1 cells before HCT. The effect of JES-6 treatment on tumor cell clearance was compared with the calcineurin inhibitor tacrolimus (TAC), which inhibits IL-2 production from donor T cells.
  3. Does JES-6-IL-2 blockage require PD-L1 expression to attenuate GvHD?
    • PD-L1−/− mice were given JES-6 treatment following HCT and compared with wildtype mice.
  4. What mechanisms are PD-L1 dependent?
    • The authors investigated the effect of JES-6 treatment on T-regulatory (Treg) cells, T-helper type 1 cells (Th1), and cytotoxic T cell type 1 (Tc1) populations in wildtype and PDL1−/− mice, at Day 6 post-HCT.
  5. Is inhibition of IL-2-Stat-5 and AKT/mTOR pathways required to attenuate GvHD?
    • Wildtype mice treated with JES-6 and IgG were compared for inhibition of IL-2-Stat-5 signaling.
    • Wildtype and PD-L1−/− JES-6-treated mice were analyzed for expression of phosphorylated AKT/mTOR.
  6. How does JES-6 preserve GvL activity?
    • Single-cell RNA sequencing (scRNA-seq) was used to generate gene cluster profiles for donor T cells in JES-6 and TAC-treated mice, at Day 7 post-HCT.
    • The percentage of Tmp, Teff, and exhausted T (Tex) cells were compared in GvHD target tissues of JES-6 and TAC-treated mice.

Effect of JES-6 treatment on GvHD and GvL

JES-6 attenuates GvHD while preserving GvL activity

  • JES-6 administration in mice reduced the severity of acute GvHD, with a reduction in symptoms including weight loss and diarrhea, when compared with both control IgG and anti-IL-2-S4B6. The authors also observed a reduction in damage of GvHD target tissues (liver, colon, and small intestine) in mice treated with JES-6 compared with control antibody groups.
  • In terms of GvL, no effect on tumor growth was observed with JES-6, with all recipients dying after 20 days. However, for mice given both splenocytes and TCD-BM cells, JES-6 treatment led to a reduction in tumor growth compared with immunoglobulin controls, with all mice surviving over 30 days without relapse.
  • Finally, using TAC as a control, the authors initially observed similar GvHD and GVL activity between the treatment groups, engrafted with spleen (2.5 × 106) and TCD-BM (2.5 × 106) cells, and inoculation with 5 × 106 Luc/BCL1 cells. However, when reducing the number of spleen cells (1.25 × 106) at the same concentration of inoculation, JES-6 treated mice managed to clear tumour cells by Day 12, while only 60% of mice treated with TAC cleared cells by Day 17 and the other 40% died by Day 30.
  • At the highest dose (10 × 106 Luc/BCL1 cells), all TAC recipients died by Day 9, indicating that under these conditions, JES-6 showed improved GvL activity.

JES-6 attenuation of GvHD requires PD-L1 expression

  • The authors observed a reduction in GvHD activity in wildtype mice treated with JES-6, but not in PD-L1−/− mice.
  • The same was observed for the yield of CD4+ T cells but not CD8+ T cells in the liver and colon, which were markedly reduced in JES-6-treated wildtype mice compared with IgG controls; however, no difference was observed in PD-L1−/−-treated mice.
  • Compared with IgG treatment, JES-6 treatment also increased the percentage of PD-1+ Eomes+ CD4+ and CD8+ T cells in the liver and colon tissues at Day 6 after HCT in the PD-L1−/− recipients. The percentages of PD-1+ Eomes+ CD4+ and CD8+ T cells in the liver and colon tissues of JES-6-treated PD-L1/ recipients, were markedly lower than in JES-6-treated wildtype recipients at Day 6 after HCT.

PD-L1 interaction and JES-6 IL-2 interference synergistically reduce the percentage of GM-CSF-producing Th1 and Tc1 cells

  • Granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing Th1 and Tc1 cells are involved in the pathogenesis of acute GvHD, with release of this inflammatory cytokine leading to recruitment of monocytes and neutrophils to produce GvHD symptoms.
  • The authors observed a reduction in the percentage of GM-CSF IFN-γ+ Th1 cells in the colon and liver of wildtype mice given JES-6, at Day 6 post-HCT compared with anti-IL-2-S4B6 controls. A reduction was also observed in PD-L1−/− mice, albeit far less than that of wildtype-treated mice.
  • JES-6 treatment reduced the percentage but not yield of Tc1 cells in the liver and colon of wildtype mice compared with control, however this reduction was again lessened in PDL1−/− mice.

PD-L1-induced proliferation of IL-10+ Tr1 cells is required for attenuation of GvHD

  • FoxP3+ Treg and FoxP3IL-10+ type 1 regulatory (Tr1) cells are required to attenuate GvHD activity. JES-6 treatment increased the percentage of FoxP3+ Treg cells among infiltrating donor-type CD4+ T cells in the liver, but not in the colon of wildtype recipients.
  • The authors did not observe any increase for either organ of PD-L1−/− mice with JES-6 treatment.
  • Foxp3IL-10+ Tr1 cells are in abundance in allo-HCT grafts. Expression of the nuclear factors Eomes and Blimp-1, is required for the proliferation of these cells, and the authors observed increased expression of such factors in CD4+ cells of wildtype mice with the JES-6 treatment compared with anti-IL-2-S4B6 and IgG controls; however, not in JES-6-treated PD-L1−/− mice.

JES-6 inhibition of IL-2-Stat-5 signalling and PD-L1 inhibition of AKT-mTOR pathways are required to attenuate GvHD

  • In wildtype mice, inhibition of the IL-2-Stat-5 pathway of CD4+ and CD8+ T cells infiltrating the colon and spleen was observed with the JES-6 treatment, at Day 6 post-HCT compared with IgG controls.
  • A reduction in phosphorylated AKT and mTOR in CD4+ and CD8+ T-cells was detected in the colon of JES-6-treated mice, unlike anti-IL-2-S4B6 treatment. In contrast, a reduced expression of phosphorylated forms was not observed in JES-6-treated PD-L1−/− mice, demonstrating PD-L1 is essential for this process.

GvL effects

JES-6 and TAC produce distinct populations of donor T cells in the spleen

  • As JES-6 treatment produced significantly greater preservation of GvL activity compared with TAC, the authors next compared the populations of donor T cells between the treatment groups.
  • scRNA-seq revealed that subsets of infiltrating CD4+ and CD8+ cells had similar expressional profiles; however, clusters of TCF-1+ CD4+ and CD8+ self-renewing memory progenitors were larger in the JES-6-treated group than in the TAC group. Such cells can further differentiate into cytolytic CD8+ T cells under CD4+ T-cell help. Thus, evidence was demonstrated for greater preservation of Tmp cells in lymphoid tissues of JES-6-treated mice.

JES-6 preserves CD8+ Tmp progenitors more effectively than TAC

  • JES-6 treatment reduced the percentage of terminally differentiated effector CD8+ T-cells in the spleen compared with TAC treatment; however, there was a greater proportion of CD107a+/Granzyme B+ subset with stronger cytolytic function.
  • Additionally, the percentage of CD8+ Tmp cells in the lymph node, liver, spleen, and colon of JES-6-treated mice, at Day 7 post-HCT were greater than the TAC group. The percentage of Teff cells were greater only in the lymph node and spleen of JES-6-treated mice compared with TAC, while conversely, the percentage of Tex cells was fewer in the lymph node and spleen for JES-6-treated mice.


Overall, these data provide preclinical evidence for the use of a monoclonal anti-IL-2 antibody, JES-6, in attenuating GvHD and preserving GvL activity. Song et al. were also able to provide insight into multiple molecular steps involved for this. Firstly, unlike previous IL-2 inhibitors, JES-6 appeared to have minimal effect on proliferation of Foxp3+ Treg cells, instead of acting primarily through inhibition of the IL-2-Stat-5 pathway, and in turn reducing GM-CSF release from donor CD4+ and CD8+ T cells. Secondly, GvL activity was produced through preservation of PD-1+ Tmp CD4+ and CD8+ cells resulting from low PD-L1 expression in lymphoid tissues. Thirdly, in GvHD target tissues, a high expression of PD-1 led to increased PD-L1 interaction in donor CD4+ and CD8+ T cells, reducing AKT-mTOR signalling, increasing Eomes and Blimp-1 expression, resulting in T-cell exhaustion.

  1. Song Q, Wang X, Wu X, et al. Tolerogenic anti–IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity. Blood. 2021;137(16):2243–2255. DOI: 10.1182/blood.2020006345